Lupus & antiphospholipid syndrome
Adverse pregnancy outcomes across SLE subgroups: significance of cardiovascular events
Authors' conclusion
LN and APS in SLE contributed to incremental risks for adverse outcomes, with the combination of LN or APS with CVEs yielding the highest point estimates.
Study context
- Population
- Pregnant individuals, California population-based birth cohort, 2005–2020
- Exposure
- SLE subgroups (with/without lupus nephritis (LN) or antiphospholipid syndrome (APS), with/without cardiovascular events (CVEs)) vs pregnant individuals without autoimmune rheumatic diseases or APS and CVEs
- SLEn = 8,422
- SLE with LNn = 903
- SLE with APSn = 513
- Outcome
- Adverse pregnancy outcomes in SLE, specifically the influence of CVEs
Methodological detailsCalifornia population-based birth cohort, adjusted relative risks
- California population-based birth cohort
- Adjusted relative risks
Main finding
As reported in the abstract
- Non-cardiac severe maternal morbidity
- 3.2-fold to 31.5-fold
- ICU admission
- 2.0-fold to 12.2-fold
- 1 year re-admission
- 2.4-fold to 6.0-fold
- Death
- 7.0-fold to 7.9-fold
- Preterm birth
- 2.3-fold to 6.8-fold
- Small-for-gestational-age infant
- 1.8-fold to 3.4-fold
- Neonatal ICU admission
- 2.1-fold to 7.9-fold
- Infant death
- 1.6-fold to 3.7-fold
Observational data: associations, not effects.
Further findings
Pregnancies complicated by CVEs
- Pregnancies complicated by CVEs: Reference denominator 7004 334 (individuals without autoimmune rheumatic diseases or APS)
Original publication
Adverse pregnancy outcomes across SLE subgroups: significance of cardiovascular events. Lupus Sci Med. Published 29 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →